Meer Mustafa

Meer is a computational biologist with a passion for answering biological questions with quantitative methods. Prior to BigHat, he was at 23andMe and Alector, leading program development towards IND and part of a larger team working on target discovery. He worked on multiple programs for neurodegenerative diseases and oncology, including Alector's AL002/TREM2 antibody for Alzheimer's Disease, authoring a publication focused on antibody MoA and inventing a patent along the way. He completed his undergraduate training at UT Dallas and graduate training at NYU/New York Genome Center with Dr. Neville Sanjana focusing on noncoding screens to find cis-regulatory elements controlling cancer.